182 related articles for article (PubMed ID: 10617291)
1. The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Castiello U; Bennett KM; Bonfiglioli C; Peppard RF
Neuropsychologia; 2000; 38(1):46-59. PubMed ID: 10617291
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
3. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
[TBL] [Abstract][Full Text] [Related]
4. Social intentions in Parkinson's disease patients: A kinematic study.
Straulino E; Scaravilli T; Castiello U
Cortex; 2015 Sep; 70():179-88. PubMed ID: 25804938
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Castiello U; Bennett KM
Neuropsychologia; 1994 Nov; 32(11):1367-82. PubMed ID: 7877745
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic effects on the implicit processing of distractor objects in Parkinson's disease.
Castiello U; Bonfiglioli C; Peppard RF
Exp Brain Res; 2000 Nov; 135(2):251-8. PubMed ID: 11131510
[TBL] [Abstract][Full Text] [Related]
7. Hand preshaping in Parkinson's disease: effects of visual feedback and medication state.
Schettino LF; Adamovich SV; Hening W; Tunik E; Sage J; Poizner H
Exp Brain Res; 2006 Jan; 168(1-2):186-202. PubMed ID: 16041510
[TBL] [Abstract][Full Text] [Related]
8. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Nissenbaum H; Quinn NP; Brown RG; Toone B; Gotham AM; Marsden CD
Psychol Med; 1987 Nov; 17(4):899-904. PubMed ID: 3432464
[TBL] [Abstract][Full Text] [Related]
9. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
10. It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
Straulino E; Scaravilli T; Bulgheroni M; D'Amico E; Castiello U
Neuropsychologia; 2016 Dec; 93(Pt A):106-115. PubMed ID: 27756693
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
12. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
14. Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
van Nuland AJ; Helmich RC; Dirkx MF; Zach H; Toni I; Cools R; den Ouden HEM
Brain; 2020 Dec; 143(11):3422-3434. PubMed ID: 33147621
[TBL] [Abstract][Full Text] [Related]
15. The co-ordination and phasing of a bilateral prehension task. The influence of Parkinson's disease.
Alberts JL; Tresilian JR; Stelmach GE
Brain; 1998 Apr; 121 ( Pt 4)():725-42. PubMed ID: 9577397
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Valldeoriola F; Grandas F; Santos-García D; Regidor I; Catalán MJ; Arbelo JM; Puente V; Mir P; Parra JC
Neurodegener Dis Manag; 2016 Aug; 6(4):289-98. PubMed ID: 27440190
[TBL] [Abstract][Full Text] [Related]
17. Should levodopa dose be reduced when switched to stalevo?
Linazasoro G; Kulisevsky J; Hernández B;
Eur J Neurol; 2008 Mar; 15(3):257-61. PubMed ID: 18215153
[TBL] [Abstract][Full Text] [Related]
18. [Drug therapy of Parkinson's disease].
Zhou XD
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
[No Abstract] [Full Text] [Related]
19. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Quinn NP; Marion MH; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
[TBL] [Abstract][Full Text] [Related]
20. Levodopa effect upon functional balance of Parkinson's disease patients.
Nova IC; Perracini MR; Ferraz HB
Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
